Compare VOYA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOYA | CELC |
|---|---|---|
| Founded | 1975 | 2011 |
| Country | United States | United States |
| Employees | 11000 | N/A |
| Industry | Life Insurance | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.0B |
| IPO Year | N/A | 2017 |
| Metric | VOYA | CELC |
|---|---|---|
| Price | $97.52 | $108.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $84.90 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.13 | N/A |
| Revenue Next Year | $3.93 | $720.19 |
| P/E Ratio | $12.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $64.50 | $13.39 |
| 52 Week High | $98.72 | $151.02 |
| Indicator | VOYA | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 77.27 | 53.91 |
| Support Level | $72.93 | $99.38 |
| Resistance Level | N/A | $117.61 |
| Average True Range (ATR) | 2.38 | 5.75 |
| MACD | 0.26 | 2.70 |
| Stochastic Oscillator | 87.07 | 71.66 |
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Retirement, Investment Management and Employee Benefits.The majority revenue is from Retirement segment.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.